August 2022 FDA Recall Difluprednate by Cipla
D-1328-2022 - Lack of Assurance of Sterility

This Class II drug recall was voluntarily initiated by Cipla on August 2, 2022 for the product Difluprednate. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1328-2022

Reason for Recall
Lack of Assurance of Sterility: Complaints received of defective container closure.
Initiated
08-02-2022
Reported
08-17-2022
Quantity
7,992 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Nationwide in the USA
Difluprednate Ophthalmic Emulsion 0.05%, For Ophthalmic Use Only, Sterile, 5 mL bottles, Manufactured by Cipla Ltd., India, Manufactured for: Cipla USA, Inc., NJ 07059, NDC 69097-341-35.

Batch or Lot Expiration Information

Lot# DEG3LC2, Exp 05/2023

Affected Packages Involved in this Recall